Long Term Safety Study of Orfadin Treatment in HT-1 Patients in Standard Clinical Care
Status:
Completed
Trial end date:
2019-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at the long term safety profile of Orfadin treatment in
patients suffering from hereditary tyrosinemia type 1 (HT-1). Patients included in the study
will use Orfadin according to normal clinical practice.